[Influence of spinal orthosis on gait and physical functioning in women with postmenopausal osteoporosis]. / Einflüsse einer Wirbelsäulenorthese auf Gangparameter und Alltagsfunktion bei Postmenopausaler Osteoporose.

INTRODUCTION: Osteoporosis is a widespread chronic bone disease leading to an increased risk of bone fractures. The most common clinical consequences are back pain, hyperkyphosis, limitations of physical functioning and activities of daily living as well as reduced quality of life. Furthermore, osteoporosis is associated with decreased strength and deficits of gait and balance, all together resulting in an increased risk of falls and a subsequent aggravation of fracture risk. Besides pharmaceutical and exercise therapy, back orthoses are increasingly being used in the therapy of osteoporosis and rehabilitation after vertebral fractures. Previous studies have shown that wearing a spinal orthosis results in a reduction of pain as well as improvements of posture and back extensor strength. To date there is no study that has evaluated the effects of a spinal orthosis on gait stability and physical functioning in patients with osteoporosis. Therefore the purpose of the present study was to assess the effects of a spinal orthosis on gait and pain-induced limitations of activities of daily living (ADL) in women with osteoporosis. METHODS: A total of 69 postmenopausal osteoporotic women with and without vertebral fractures were randomly assigned to receive either a spinal orthosis (Thämert Osteo-med intervention group n=35; average age 74 ± 8.3 years, height 158.3 ± 6.3 cm, weight 62.8 ± 9.6 kg, t-score -2.6 ± 1.0, number of vertebral fractures 1.4 ± 2.0) or to a waiting list control group (n= 34, age 74.1 ± 7.7 years, height 159.6 ± 5.9 cm, weight 65.4 ± 11.3 kg, t-score -2.9± 0.8, number of vertebral fractures: 0.9 ± 1.2). The following outcome measures were collected at baseline and at 3 and 6 months follow-up: gait parameters including gait analysis: velocity, stride length and width, double support time (% of gait cycle) and perceived limitations in activities of daily living (numeric rating scale 1-10; 1=best, 10= worst situation). RESULTS: The ANCOVA indicated a significant reduction of the double support time at 6 months in the intervention group (p < 0.05) without a significant influence of the covariate vertebral fractures status. The other parameters remained unchanged (p > 0 .05). Regarding the pain-related ADL limitations there were significant differences in the amount of change over the study period depending on the baseline value. Stratified into terciles (≤ 2.5; 2.6-5.0; >5) patients with initially high values showed a significantly greater reduction in perceived ADL restrictions compared to patients in the lowest tercile (-2.7 ± 2.7 versus 1.5 ± 2.1). CONCLUSION: The study demonstrated that wearing a spinal orthosis introduced a reduction in double support time associated with a beneficial impact on gait stability. Furthermore, there was a positive effect on pain-related restrictions of ADL evident in women with a high level of limitations at baseline. Besides previously shown reductions in pain, improvements in back extensor strength and correction of posture, the application of a spinal orthosis may induce advantages for gait stability and physical functioning in women with postmenopausal osteoporosis. Future studies should consider a longer follow-up to evaluate possible effects on the risk of falling and fractures.

Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac.

The therapeutic equivalence and safety of treatment for 21 days with 400 mg t.i.d. oxaceprol (n = 132) and 50 mg t.i.d. diclofenac (n = 131) were assessed in a multicentre, randomised, double-blind study of a mixed population of patients with osteoarthritis of the knee and/or hip. In a per-protocol analysis of efficacy, the mean Lequesne index decreased by 2.5 points in the oxaceprol group (n = 109) and by 2.8 points in the diclofenac group (n = 109). The 95% confidence interval for the end-point difference revealed therapeutic equivalence. This was confirmed by assessments (visual analogue scale) of pain at rest, weight-bearing pain, pain on standing and pain on movement, all of which decreased to a similar extent under both treatments. The pain-free walking time increased in both groups from 10 min to 25 min by the end of the treatment period. Mobility was also increased to a similar extent by both drugs. The physicians assessed treatment as good or very good in 45-46% of patients in both groups. In all patients who received treatment, 28 and 37 adverse events were reported by 25 out of 132 (18.9%) and 33 out of 131 (25.2%) patients treated with oxaceprol and diclofenac, respectively. In 15 patients (11.4%) with 15 adverse events in the oxaceprol group and 25 patients (19.1%) with 27 adverse events in the diclofenac group, a relation to the medication was considered probable. The difference between the groups was statistically significant (p = 0.04106) for the number of these adverse events. Oxaceprol is therapeutically equivalent to diclofenac, but better tolerated than diclofenac in the treatment of osteoarthritis.

[Holding device for x-ray determination of injuries in collateral ligaments of the metacarpophalangeal joint of the thumb]. / Halteapparat zum röntgenologischen Nachweis von Läsionen des ulnaren Seitenbandes des Daumengrundgelenkes.

A device is described with which to hold the thumb during radiological evaluation following possible injury to the ulnar collateral ligament. Its advantages and use in other digits are discussed.